<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39397158</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>13</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>16</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>13</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Oxoammonium salts exert antiviral effects against coronavirus via denaturation of their spike proteins.</ArticleTitle><Pagination><StartPage>23934</StartPage><MedlinePgn>23934</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">23934</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-024-75097-7</ELocationID><Abstract><AbstractText>Severe acute respiratory syndrome-coronavirus-2 (SARS-CoV2) infection has forced social changes worldwide. Development of potent antiviral agents is necessary to prevent future pandemics. Titanium oxide, a photocatalyst, is a long-acting antiviral agent; however, its effects are weakened in the dark. Therefore, new antiviral substances that can be used in the dark are needed. Two types of nitroxyl radicals, 2,2,6,6-tetramethylpiperidine N-oxyl (TEMPO) and 2-azaadamantane N-oxyl (AZADO), are commonly used as oxidation catalysts utilizing oxygen in the air as the terminal oxidant. Therefore, in this study, we aimed to evaluate the potential of these radicals as antiviral compounds with sustained activity even in the dark. We evaluated the antiviral effects of oxoammonium salts corresponding to TEMPO and AZADO (TEMPO-Oxo and AZADO-Oxo, respectively), which are the active forms of nitroxyl radicals in oxidation reactions. TEMPO-Oxo and AZADO-Oxo inhibited the binding of SARS-CoV2 spike protein receptor-binding domain (S-RBD) to angiotensin-converting enzyme 2. Notably, AZADO-Oxo exhibited a 10-fold stronger inhibitory effect than TEMPO-Oxo. TEMPO-Oxo and AZADO-Oxo also denatured S-RBD; however, effects of AZADO-Oxo were 10-fold stronger than those of TEMPO-Oxo and did not change in the dark. Some S-RBD peptides treated with AZADO-Oxo were cleaved at the N-terminal side of tyrosine residues. TEMPO-Oxo and AZADO-Oxo exhibited concentration-dependent antiviral effects against feline coronavirus. In conclusion, active forms of the nitroxyl radicals, TEMPO-Oxo and AZADO-Oxo, exerted antiviral effects by denaturing S-RBD, regardless of the presence or absence of light, suggesting their potential as novel antiviral agents.</AbstractText><CopyrightInformation>Â© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Segawa</LastName><ForeName>Ryosuke</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Laboratory of Pharmacotherapy of Life-Style Related Diseases, Graduate School of Pharmaceutical Sciences, Tohoku University, 6-3 Aramaki-aoba, Aoba-ku, Sendai, 980-8578, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sasano</LastName><ForeName>Yusuke</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Laboratory of Synthetic Chemistry, Graduate School of Pharmaceutical Sciences, Tohoku University, 6-3 Aramaki-aoba, Aoba-ku, Sendai, 980-8578, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hatakawa</LastName><ForeName>Yusuke</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Laboratory of Bio-analytical Chemistry, Graduate School of Pharmaceutical Sciences, Tohoku University, 6-3 Aramaki-aoba, Aoba-ku, Sendai, 980-8578, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fujisawa</LastName><ForeName>Yuto</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Laboratory of Pharmacotherapy of Life-Style Related Diseases, Graduate School of Pharmaceutical Sciences, Tohoku University, 6-3 Aramaki-aoba, Aoba-ku, Sendai, 980-8578, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Akutsu</LastName><ForeName>Shuhei</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Laboratory of Synthetic Chemistry, Graduate School of Pharmaceutical Sciences, Tohoku University, 6-3 Aramaki-aoba, Aoba-ku, Sendai, 980-8578, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Uchimura</LastName><ForeName>Masanobu</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Advanced Materials and Processing Laboratory, Research Division, Nissan Motor Co., Ltd, 1 Natsushima-cho, Yokosuka, Kanagawa, 237-8523, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ikura</LastName><ForeName>Ami</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Advanced Materials and Processing Laboratory, Research Division, Nissan Motor Co., Ltd, 1 Natsushima-cho, Yokosuka, Kanagawa, 237-8523, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matsumoto</LastName><ForeName>Kota</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Advanced Materials and Processing Laboratory, Research Division, Nissan Motor Co., Ltd, 1 Natsushima-cho, Yokosuka, Kanagawa, 237-8523, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sone</LastName><ForeName>Kazuki</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Advanced Materials and Processing Laboratory, Research Division, Nissan Motor Co., Ltd, 1 Natsushima-cho, Yokosuka, Kanagawa, 237-8523, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oe</LastName><ForeName>Tomoyuki</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Laboratory of Bio-analytical Chemistry, Graduate School of Pharmaceutical Sciences, Tohoku University, 6-3 Aramaki-aoba, Aoba-ku, Sendai, 980-8578, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iwabuchi</LastName><ForeName>Yoshiharu</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Laboratory of Synthetic Chemistry, Graduate School of Pharmaceutical Sciences, Tohoku University, 6-3 Aramaki-aoba, Aoba-ku, Sendai, 980-8578, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ito</LastName><ForeName>Masashi</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Advanced Materials and Processing Laboratory, Research Division, Nissan Motor Co., Ltd, 1 Natsushima-cho, Yokosuka, Kanagawa, 237-8523, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Advanced Institute for Materials Research, Tohoku University, 2-1-1 Katahira, Aoba-ku, Sendai, 980-8577, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hirasawa</LastName><ForeName>Noriyasu</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Laboratory of Pharmacotherapy of Life-Style Related Diseases, Graduate School of Pharmaceutical Sciences, Tohoku University, 6-3 Aramaki-aoba, Aoba-ku, Sendai, 980-8578, Japan. noriyasu.hirasawa.c7@tohoku.ac.jp.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>21H05210</GrantID><Agency>Japan Society for the Promotion of Science</Agency><Country /></Grant><Grant><GrantID>22H02739</GrantID><Agency>Japan Society for the Promotion of Science</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003497">Cyclic N-Oxides</NameOfSubstance></Chemical><Chemical><RegistryNumber>VQN7359ICQ</RegistryNumber><NameOfSubstance UI="C003959">TEMPO</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000657845">spike protein, SARS-CoV-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009589">Nitrogen Oxides</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.17.23</RegistryNumber><NameOfSubstance UI="D000085962">Angiotensin-Converting Enzyme 2</NameOfSubstance></Chemical><Chemical><RegistryNumber>GFQ4MMS07W</RegistryNumber><NameOfSubstance UI="C039900">nitroxyl</NameOfSubstance></Chemical><Chemical><RegistryNumber>PJY633525U</RegistryNumber><NameOfSubstance UI="D000218">Adamantane</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.17.23</RegistryNumber><NameOfSubstance UI="C000705307">ACE2 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="Y">Antiviral Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064370" MajorTopicYN="Y">Spike Glycoprotein, Coronavirus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003497" MajorTopicYN="N">Cyclic N-Oxides</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009589" MajorTopicYN="N">Nitrogen Oxides</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000085962" MajorTopicYN="N">Angiotensin-Converting Enzyme 2</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="N">COVID-19 Drug Treatment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000218" MajorTopicYN="N">Adamantane</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>We received a research grant from Nissan Motor Co., Ltd. Our study relates to the patent (patent applicant is Nissan Motor Co., Ltd., inventor is M.I., A.I., M.U., N.H., Y.S., Y.I., and R.S., application number is PCT/JP2023/031213, patent pending). Other author have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>4</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>14</Day><Hour>0</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>14</Day><Hour>0</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>13</Day><Hour>23</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39397158</ArticleId><ArticleId IdType="pmc">PMC11471821</ArticleId><ArticleId IdType="doi">10.1038/s41598-024-75097-7</ArticleId><ArticleId IdType="pii">10.1038/s41598-024-75097-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Abdelrahman, Z., Li, M. &amp; Wang, X. Comparative review of SARS-CoV-2, SARS-CoV, MERS-CoV, and Influenza a respiratory viruses. Front. Immunol. 10.3389/fimmu.2020.552909 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7516028</ArticleId><ArticleId IdType="pubmed">33013925</ArticleId></ArticleIdList></Reference><Reference><Citation>Foster, H. A., Ditta, I. B., Varghese, S. &amp; Steele, A. Photocatalytic disinfection using titanium dioxide: Spectrum and mechanism of antimicrobial activity. Appl. Microbiol. Biotechnol. 90, 1847â1868 (2011). 10.1007/s00253-011-3213-7</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7079867</ArticleId><ArticleId IdType="pubmed">21523480</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakano, R. et al. Inactivation of various variant types of SARS-CoV-2 by indoor-light-sensitive TiO2-based photocatalyst. Sci. Rep.12, 5804 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9010443</ArticleId><ArticleId IdType="pubmed">35422456</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwabuchi, Y. Discovery and Exploitation of AZADO: The highly active Catalyst for Alcohol Oxidation. Chem. Pharm. Bull. (Tokyo). 61, 1197â1213 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">24292782</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasano, Y. et al. Highly chemoselective aerobic oxidation of amino alcohols into amino carbonyl compounds. Angewandte Chemie-Int. Ed.53, 3236â3240 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24554411</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoover, J. M. &amp; Stahl, S. S. Highly practical copper(I)/TEMPO catalyst system for chemoselective aerobic oxidation of primary alcohols. J. Am. Chem. Soc.133, 16901â16910 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3197761</ArticleId><ArticleId IdType="pubmed">21861488</ArticleId></ArticleIdList></Reference><Reference><Citation>Shibuya, M., Osada, Y., Sasano, Y., Tomizawa, M. &amp; Iwabuchi, Y. Highly efficient, organocatalytic aerobic alcohol oxidation. J. Am. Chem. Soc.133, 6497â6500 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21473575</ArticleId></ArticleIdList></Reference><Reference><Citation>Seki, Y. et al. Serine-selective aerobic cleavage of peptides and a protein using a water-soluble copper-organoradical conjugate. Angewandte Chemie-Int. Ed.53, 6501â6505 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24826926</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexander, S. A., Kyi, C. &amp; Schiesser, C. H. Nitroxides as anti-biofilm compounds for the treatment of Pseudomonas aeruginosa and mixed-culture biofilms. Org. Biomol. Chem.13, 4751â4759 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25804546</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann, M. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 181, 271â280e8 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7102627</ArticleId><ArticleId IdType="pubmed">32142651</ArticleId></ArticleIdList></Reference><Reference><Citation>Tai, W. et al. Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: Implication for development of RBD protein as a viral attachment inhibitor and vaccine. Cell. Mol. Immunol.17, 613â620 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7091888</ArticleId><ArticleId IdType="pubmed">32203189</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan, R. et al. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science. 367 (2020). https://www.science.org</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7164635</ArticleId><ArticleId IdType="pubmed">32132184</ArticleId></ArticleIdList></Reference><Reference><Citation>Clausen, T. M. et al. SARS-CoV-2 infection depends on cellular heparan sulfate and ACE2. Cell. 183, 1043â1057.e15 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7489987</ArticleId><ArticleId IdType="pubmed">32970989</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalra, R. S. &amp; Kandimalla, R. Engaging the spikes: Heparan sulfate facilitates SARS-CoV-2 spike protein binding to ACE2 and potentiates viral infection. Signal Transduct. Targeted Therapy. 6. (2021). 10.1038/s41392-021-00470-1</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7844799</ArticleId><ArticleId IdType="pubmed">33514685</ArticleId></ArticleIdList></Reference><Reference><Citation>Shibuya, M., Tomizawa, M., Suzuki, I. &amp; Iwabuchi, Y. 2-Azaadamantane N-oxyl (AZADO) and 1-Me-AZADO: Highly efficient organocatalysts for oxidation of alcohols. J. Am. Chem. Soc.128, 8412â8413 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16802802</ArticleId></ArticleIdList></Reference><Reference><Citation>Jamison, D. A. et al. A comprehensive SARS-CoV-2 and COVID-19 review, Part 1: Intracellular overdrive for SARS-CoV-2 infection. Eur. J. Hum. Genet. 30, 889â898 (2022). 10.1038/s41431-022-01108-8</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9108708</ArticleId><ArticleId IdType="pubmed">35577935</ArticleId></ArticleIdList></Reference><Reference><Citation>Ke, Z. et al. Structures and distributions of SARS-CoV-2 spike proteins on intact virions. Nature. 588, 498â502 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7116492</ArticleId><ArticleId IdType="pubmed">32805734</ArticleId></ArticleIdList></Reference><Reference><Citation>Sender, R. et al. The total number and mass of SARS-CoV-2 virions. 10.1073/pnas.2024815118/-/DCSupplemental</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8237675</ArticleId><ArticleId IdType="pubmed">34083352</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu, Y. et al. Inactivation of SARS-CoV-2 and photocatalytic degradation by TiO2 photocatalyst coatings. Sci. Rep.12, (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9512902</ArticleId><ArticleId IdType="pubmed">36163418</ArticleId></ArticleIdList></Reference><Reference><Citation>Palumbo, P., Prota, G. Isolation of a new intermediate in the oxidative conversion of 5,6-dihydroxyindole-2-carboxylic acid to melanin. Tetrahedron Lett.28 (1987).</Citation></Reference><Reference><Citation>Nakagawa, S. et al. pH stability and antioxidant power of CycloDOPA and its derivatives. Molecules23, (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6222597</ArticleId><ArticleId IdType="pubmed">30081515</ArticleId></ArticleIdList></Reference><Reference><Citation>Tresnan, D. B., Levis, R., And &amp; Holmes, K. V. Feline aminopeptidase N serves as a receptor for Feline, Canine, Porcine, and human coronaviruses in Serogroup I. J. Virol. 70 (1996). https://journals.asm.org/journal/jvi</Citation><ArticleIdList><ArticleId IdType="pmc">PMC190961</ArticleId><ArticleId IdType="pubmed">8970993</ArticleId></ArticleIdList></Reference><Reference><Citation>Gozdziewska, M., Cichowicz, G., Markowska, K., Zawada, K. &amp; Megiel, E. Nitroxide-coated silver nanoparticles: Synthesis, surface physicochemistry and antibacterial activity. RSC Adv.5, 58403â58415 (2015).</Citation></Reference><Reference><Citation>Hayashi, M., Shibuya, M. &amp; Iwabuchi, Y. Oxidative conversion of silyl enol ethers to Î±,Î²-unsaturated ketones employing oxoammonium salts. Org. Lett.14, 154â157 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22181054</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider, C. A., Rasband, W. S. &amp; Eliceiri, K. W. NIH Image to ImageJ: 25 years of image analysis. Nat. Methods. 9, 671â675 (2012). 10.1038/nmeth.2089</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5554542</ArticleId><ArticleId IdType="pubmed">22930834</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>